04239cam a2200709Ma 4500 ocn831464032 OCoLC 20171107082433.0 m o d cr |n||||||||| 121010s2013 nju ob 001 0 eng d 9781118487471 (pbk.) 1118487478 (pbk.) 9781283917421 (MyiLibrary) 1283917424 (MyiLibrary) 9781118511251 (electronic bk.) 1118511255 (electronic bk.) 9781118511299 (electronic bk.) 1118511298 (electronic bk.) 9781118511329 (electronic bk.) 1118511328 (electronic bk.) EB00063788 Recorded Books AU@ 000050591439 AU@ 000051955577 AU@ 000052918221 DEBBG BV040884467 DEBBG BV041052577 DEBBG BV041906704 DEBSZ 397453892 DKDLA 820120-katalog:000600440 NZ1 14976927 DEBBG BV043395679 (OCoLC)831464032 (OCoLC)823389919 (OCoLC)829353805 (OCoLC)864914474 (OCoLC)880910023 (OCoLC)961488066 (OCoLC)962624123 684D5251-34C3-4198-A03A-18F445996D72 OverDrive, Inc. http://www.overdrive.com AZU eng pn AZU OCLCO CCO IDEBK E7B GPM OCLCF YDXCP RECBK MHW EBLCP N$T DG1 TEFOD DEBSZ UKDOC LRU GGVRL OCLCQ AU@ CDX DEBBG TEFOD OCLCQ COO OCLCQ NKT AZK MAIN HD9665.5 .L36 2013eb BUS 070130 bisacsh 338.4/76151 23 LaMattina, John L. Devalued and Distrusted : Can the Pharmaceutical Industry Restore Its Broken Image? / John L. LaMattina, PhD. [electronic resource] Hoboken, New Jersey : Wiley, [2013] 1 online resource (ix, 125 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier data file rda Includes index. Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts. Includes bibliographical references and index. 1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts. "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Provided by publisher. Print version record. Pharmaceutical industry Corrupt practices. Medical. MEDICAL Pharmacology. bisacsh Pharmaceutical industry Corrupt practices. fast (OCoLC)fst01060133 Electronic books. Print version: LaMattina, John L. Devalued and distrusted. Hoboken, New Jersey : John Wiley & Sons, Inc., [2013] 9781118487471 (DLC) 2012032915 (OCoLC)811597120 http://onlinelibrary.wiley.com/book/10.1002/9781118511329 Wiley Online Library ddc BK 206601 206601